Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Long Term Incentive Scheme

7 Dec 2007 07:00

Futura Medical PLC07 December 2007 For immediate release 7 December 2007 Futura Medical Plc ("Futura" or "the Company") Long Term Incentive Scheme Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovativeproducts for the consumer healthcare market, announces the introduction of along term incentive scheme for the Executive Directors under which shares willbe awarded subject to the achievement of key milestone events at the Company. The Board believes that this Long Term Incentive Scheme ("LTIS"), which has beendeveloped and reviewed over the past 12 months, is in the interests of allshareholders as it aligns the interests of the Company's Directors with those ofall other shareholders. The Executive Directors currently have beneficial interests in 1,062,687 Futurashares representing 1.8% of the Company's issued share capital and also holdexisting options over 350,000 Futura shares which currently represent 0.6% ofthe Company's issued share capital before the introduction of this LTIS. Therehave been no new grants of options to Directors since 22 March 2005. The actual quantum of the awards received by the Executive Directors will dependon achieving set milestones and the share price at the time relative to targetsset in advance. As a guide, if all the approved milestones are achieved at theshare price targets over the next 36 months then the additional shares issued inafter tax settlement would be equivalent to approximately 1.3% of the currentshare capital. The detailed scheme rules will be available shortly on theCorporate Governance pages of the Company's website. For any further information please contact:Futura Medical plcJames Barder, Chief Executive Tel: +44 (0) 1483 685 670mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk Canaccord Adams Tel: +44 (0) 20 7050 6500Mark Ashurst / Adria Da Breo For any media enquiries please contact:Buchanan Communications Tel: +44 (0) 020 7466 5000Mark Court / Rebecca Dietrich Notes Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products forconsumer healthcare. The Company is developing a portfolio of products and itsstrategy is to license their manufacture and distribution to majorpharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market ofthe London Stock Exchange. www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Dec 20199:05 amRNSSecond Price Monitoring Extn
13th Dec 20199:00 amRNSPrice Monitoring Extension
10th Dec 20194:40 pmRNSSecond Price Monitoring Extn
10th Dec 20194:35 pmRNSPrice Monitoring Extension
10th Dec 201911:05 amRNSSecond Price Monitoring Extn
10th Dec 201911:00 amRNSPrice Monitoring Extension
10th Dec 20199:05 amRNSSecond Price Monitoring Extn
10th Dec 20199:00 amRNSPrice Monitoring Extension
10th Dec 20197:00 amRNSTop Line Results from MED2005 Phase 3 study
6th Dec 20194:10 pmRNSBlock Listing Six Monthly Return
22nd Nov 201911:48 amRNSHolding(s) in Company
20th Nov 20194:05 pmRNSHolding(s) in Company
20th Nov 20194:04 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSPublishes Fireside Chat with Prof Wayne Hellstrom
11th Nov 201912:44 pmRNSHolding(s) in Company
29th Oct 201910:03 amRNSHolding(s) in Company
28th Oct 20194:12 pmRNSMED2005 Safety and Efficacy Data Reported at SMSNA
23rd Oct 201912:46 pmRNSChange of Auditor
21st Oct 20197:00 amRNSFinal Dosing of Last Patient in MED2005 Ph3 study
15th Oct 20195:44 pmRNSFutura Medical to Present Data on MED2005 at SMSNA
15th Oct 20195:42 pmRNSDirector / PCA Shareholding
18th Sep 20195:42 pmRNSDirector/PDMR Shareholding
16th Sep 201910:11 amRNSHolding(s) in Company
13th Sep 20194:40 pmRNSSecond Price Monitoring Extn
13th Sep 20194:35 pmRNSPrice Monitoring Extension
13th Sep 201911:46 amRNSHolding(s) in Company
12th Sep 20199:05 amRNSSecond Price Monitoring Extn
12th Sep 20199:00 amRNSPrice Monitoring Extension
11th Sep 20194:40 pmRNSSecond Price Monitoring Extn
11th Sep 20194:35 pmRNSPrice Monitoring Extension
11th Sep 20197:00 amRNSInterim Results for Six Months ended 30 June 2019
10th Sep 20197:00 amRNSFutura Announces Joint Venture Collaboration
16th Aug 20194:37 pmRNSHolding(s) in Company
12th Aug 20193:21 pmRNSDirector/PDMR Shareholding
12th Aug 20197:00 amRNSNotice of Interim Results
23rd Jul 20192:06 pmRNSSecond Price Monitoring Extn
23rd Jul 20192:00 pmRNSPrice Monitoring Extension
5th Jul 20193:54 pmRNSHolding(s) in Company
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:36 pmRNSPrice Monitoring Extension
25th Jun 20194:47 pmRNSDirector/PDMR Shareholding
24th Jun 20194:42 pmRNSAGM Statement
24th Jun 20197:00 amRNSAGM Statement
19th Jun 20197:00 amRNSRecruitment completed for MED2005 Phase 3 study
30th May 20197:00 amRNSBlock listing Interim Review
30th May 20197:00 amRNSNotice of AGM
29th May 201910:47 amRNSHolding(s) in Company
23rd May 20197:00 amRNSLiberum Appointed as Nominated Adviser & Broker
8th May 20192:05 pmRNSSecond Price Monitoring Extn
8th May 20192:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.